The mutagenic potential of BCP was evaluated by a bacterial reverse mutation assay, according to OECD TG471 (OECD, 2020 [22]). The four histidine auxotroph strains of Salmonella typhimurium TA100, TA1535, TA98, and TA1537, along with a tryptophan auxotroph strain of Escherichia coli, WP2 uvrA (pKM101), were used for bacterial reverse mutation testing (Green and Muriel, 1976; Maron and Ames, 1983 [23, 24]). To induce a metabolic activation system, S9 fraction (Molecular toxicology Inc., Lot No. 4230), a mitochondrial fraction of liver homogenated in SD rats, was added with Cofactor-1 (Genogen Co. Ltd, Lot No. 2009608 Ⅰ). The test strains were exposed to the test article using the pre-incubation method. Based on the results of a range-finding test conducted on the test article, dose ranges were determined using the five test strains in both the presence and absence of the metabolic activation system with two plates per dose. In this study, the highest dose was set at 5,000 μg/plate for all test strains, and six-serial diluted concentrations (5,000, 1,250, 313, 78.1, 19.5, and 4.88 μg/plate) were tested in the main study. The colonies were counted using an automated colony counter.

Note: The content above has been extracted from a research article, so it may not display correctly.

Please log in to submit your questions online.
Your question will be posted on the Bio-101 website. We will send your questions to the authors of this protocol and Bio-protocol community members who are experienced with this method. you will be informed using the email address associated with your Bio-protocol account.

We use cookies on this site to enhance your user experience. By using our website, you are agreeing to allow the storage of cookies on your computer.